Zimbabwe has turned down a major American healthcare agreement worth 367 million US dollars (£272m) spanning five years because of the United States' request for sensitive data.
This rejection was revealed after a government memo from December was disclosed, indicating that President Emmerson Mnangagwa believed the arrangement was "skewed".
A government spokesperson later clarified that the US was requesting genetic material for research and profit but refused to share the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable task of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated over $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for more negotiations to find a agreement suitable to all parties so the nation's vital HIV treatment initiative can continue.
Broader Implications
Zimbabwe's decision comes after a comparable case in Kenya, where a court halted a similar health funding agreement following legal challenges were filed about the security of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had administered aid for the US government, but Trump stated its spending was "inefficient" and his administration was seeking direct bilateral agreements to enhance transparency and accountability.
As per statements, Sixteen nations in Africa have so far signed these new agreements, constituting more than $18.3bn of fresh investment.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment through US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any equivalent guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"Put simply, our country would supply the raw materials for medical research with no certainty that the final treatments would be accessible to our people if a new disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were disrupting structures already established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with future global health emergencies.
"This system is intended to guarantee that when a nation contributes its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to develop them."
These objections over the US deal "are not meant as opposition to America," Mangwana stressed.
"We encourage continued discussions with our American counterparts on how future collaboration could be arranged in a way that honours the independence and dignity of each country."
Health Experts Response
A leading public health body expressed it understood the official position, but suggested that talks should continue considering a large portion of the country's HIV programmes depended on foreign aid.
"If specific concerns arise, including those involving data governance or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," it added.
The situation highlights the continuing debate between receiving much-needed foreign assistance and safeguarding local interests in an ever more data-driven world.